Corcept may have another arrow in its quiver to potentially use against Teva and the other generics.
This has to do with two issued patents 10,314,850 (issued 3-2019) and an new follow-up to that 10,780,097 (issued 9-2020).
The first tilted Use of ACTH in assessment and treatment of Hypokalemia in Cushing's patients and the second titled "Use of Cortisol in Assessment and Treatment of Hypokalemia in Cushing's Patients.
Hypokalemia is a common (1/3 +) issue that needs to be managed and thus the use of lab test for ACTH and/or Cortisol in better able to asses and manage that serious side-effect is directly relevant to the use of Mife or other GR modulators for Cushing's.
I wonder what the litigation strategy will be -- so far Corcept has not asserted these patents in the case against the generics Teva or Sun.